Clinical trial
Study Evaluating the Safety and Tolerability of a New Intravenous Formulation of…
NCT00464802 · Bausch Health Americas, Inc., Industry · Completed
Key facts
| NCT number | NCT00464802 |
|---|---|
| Title | Study Evaluating the Safety and Tolerability of a New Intravenous Formulation of MOA-728 in Healthy Subjects |
| Official title | A Double-Blind, Placebo-Controlled, Multiple-Dose, 2-Period Crossover Study to Evaluate the Safety and Tolerability of a New Intravenous Formulation of MOA-728 in Comparison With the Current Formulation in Healthy Subjects |
| Lead sponsor | Bausch Health Americas, Inc., Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Healthy |
| Intervention type | Drug |
| Interventions | MOA-728 |
| Enrollment | 36 |
| Start date | Apr 1, 2007 |
| Completion | Jun 1, 2007 |
| First posted | Apr 24, 2007 |
| Last update posted | Nov 25, 2019 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: